Pipeline Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine BioPharma DiveThe startup is developing modified DNA therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.PipelineGene Therapy PlatformRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioPharma Dive The startup is developing modified DNA therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. PipelineGene Therapy PlatformRead full story Post navigation Previous: FDA kicks off review of Roche’s Gazyva for wider lupus useNext: The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
